Giudici Nicola, Seiler Roland
Department of Urology, Spitalzentrum Biel, Biel 2501, Switzerland.
Department of BioMedical Research, University of Bern, Bern 3010, Switzerland.
World J Clin Oncol. 2024 Jul 24;15(7):835-839. doi: 10.5306/wjco.v15.i7.835.
The majority of bladder cancers (BCs) are non-muscle invasive BCs (NMIBCs) and show the morphology of a conventional urothelial carcinoma (UC). Aberrant morphology is rare but can be observed. The classification and characterization of histologic subtypes (HS) in UC in BC have mainly been described in muscle invasive bladder cancer (MIBC). However, the currently used classification is applied for invasive urothelial neoplasm and therefore, also valid for a subset of NMIBC. The standard transurethral diagnostic work-up misses the presence of HS in NMIBC in a considerable percentage of patients and the real prevalence is not known. HS in NMIBC are associated with an aggressive phenotype. Consequently, clinical guidelines categorize HS of NMIBC as "(very) high-risk" tumors and recommend offering radical cystectomy to these patients. Alternative strategies for bladder preservation can only be offered to highly selected patients and ideally within clinical trials. Novel treatment strategies and biomarkers have been established MIBC and NMIBC but have not been comprehensively investigated in the context of HS in NMIBC. Further evaluation prior to implementation into clinical practice is needed.
大多数膀胱癌(BC)是非肌层浸润性膀胱癌(NMIBC),呈现传统尿路上皮癌(UC)的形态。异常形态虽罕见但可观察到。BC中UC的组织学亚型(HS)的分类和特征主要在肌层浸润性膀胱癌(MIBC)中有所描述。然而,目前使用的分类适用于浸润性尿路上皮肿瘤,因此,对一部分NMIBC也有效。标准的经尿道诊断检查在相当比例的患者中会遗漏NMIBC中HS的存在,其实际患病率尚不清楚。NMIBC中的HS与侵袭性表型相关。因此,临床指南将NMIBC的HS归类为“(非常)高危”肿瘤,并建议对这些患者进行根治性膀胱切除术。膀胱保留的替代策略只能提供给经过严格挑选的患者,理想情况下是在临床试验范围内。针对MIBC和NMIBC已经建立了新的治疗策略和生物标志物,但在NMIBC的HS背景下尚未进行全面研究。在应用于临床实践之前需要进一步评估。